SE8702463D0 - LIGANDS AND METHODS FOR AUGMENTING B-CELL PROLIFERATION - Google Patents

LIGANDS AND METHODS FOR AUGMENTING B-CELL PROLIFERATION

Info

Publication number
SE8702463D0
SE8702463D0 SE8702463A SE8702463A SE8702463D0 SE 8702463 D0 SE8702463 D0 SE 8702463D0 SE 8702463 A SE8702463 A SE 8702463A SE 8702463 A SE8702463 A SE 8702463A SE 8702463 D0 SE8702463 D0 SE 8702463D0
Authority
SE
Sweden
Prior art keywords
cell proliferation
ligands
augmenting
methods
proliferation
Prior art date
Application number
SE8702463A
Other languages
Swedish (sv)
Other versions
SE8702463L (en
SE504675C2 (en
Inventor
J Ledbetter
E A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of SE8702463D0 publication Critical patent/SE8702463D0/en
Publication of SE8702463L publication Critical patent/SE8702463L/en
Publication of SE504675C2 publication Critical patent/SE504675C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Abstract

A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.
SE8702463A 1986-06-13 1987-06-12 Ligands to Increase B-Cell Proliferation SE504675C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (3)

Publication Number Publication Date
SE8702463D0 true SE8702463D0 (en) 1987-06-12
SE8702463L SE8702463L (en) 1987-12-14
SE504675C2 SE504675C2 (en) 1997-04-07

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8702463A SE504675C2 (en) 1986-06-13 1987-06-12 Ligands to Increase B-Cell Proliferation

Country Status (22)

Country Link
JP (1) JPH0762040B2 (en)
KR (1) KR910004100B1 (en)
AT (1) AT398437B (en)
AU (1) AU617087B2 (en)
BE (1) BE1000587A4 (en)
CA (1) CA1338781C (en)
CH (1) CH676600A5 (en)
CY (1) CY1681A (en)
DE (1) DE3719398C2 (en)
DK (1) DK173940B1 (en)
FR (1) FR2607136B1 (en)
GB (1) GB2191494B (en)
GR (1) GR870930B (en)
HK (1) HK10293A (en)
IE (1) IE60486B1 (en)
IL (1) IL82841A (en)
IT (1) IT1208649B (en)
LU (1) LU86919A1 (en)
NL (1) NL195022C (en)
PT (1) PT85073B (en)
SE (1) SE504675C2 (en)
SG (1) SG118992G (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (en) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma PHARMACEUTICAL COMPOSITION FOR IMMUNITY MODULATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (en) * 1983-06-27 1984-12-28 Centre Nat Rech Scient ANTITUMOR IMMUNOTOXIN, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND ITS USE IN VITRO
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
KR910004100B1 (en) 1991-06-22
DE3719398C2 (en) 1996-03-28
HK10293A (en) 1993-02-19
DK302287A (en) 1987-12-14
NL195022C (en) 2003-06-18
IT8720899A0 (en) 1987-06-12
AU617087B2 (en) 1991-11-21
IE60486B1 (en) 1994-07-27
JPH0762040B2 (en) 1995-07-05
SE8702463L (en) 1987-12-14
SE504675C2 (en) 1997-04-07
GR870930B (en) 1987-12-16
GB2191494B (en) 1990-08-22
BE1000587A4 (en) 1989-02-14
GB8713650D0 (en) 1987-07-15
PT85073A (en) 1987-07-01
FR2607136A1 (en) 1988-05-27
IE871563L (en) 1987-12-13
DE3719398A1 (en) 1988-01-28
LU86919A1 (en) 1989-03-08
PT85073B (en) 1990-07-31
IL82841A (en) 1992-11-15
AT398437B (en) 1994-12-27
CY1681A (en) 1993-10-10
DK173940B1 (en) 2002-03-04
IT1208649B (en) 1989-07-10
JPS6480299A (en) 1989-03-27
DK302287D0 (en) 1987-06-12
CA1338781C (en) 1996-12-10
IL82841A0 (en) 1987-12-20
GB2191494A (en) 1987-12-16
NL8701371A (en) 1988-01-04
SG118992G (en) 1993-01-29
KR880000582A (en) 1988-03-28
AU7421487A (en) 1987-12-17
CH676600A5 (en) 1991-02-15
ATA151387A (en) 1994-04-15
FR2607136B1 (en) 1989-09-15

Similar Documents

Publication Publication Date Title
ATE47155T1 (en) MONOCLONAL ANTIBODY.
ZA876807B (en) Monoclonal antibodies against human tumor necrosis factor(tnf),and use thereof
SE8104494L (en) ALKYLED OR ARYLEDED SILICAR CARBID PREPOLYMERS
ATE45285T1 (en) ANTIDIOTYPE ANTIBODIES INDUCED IMMUNE RESPONSE TO TUMORS AND VIRUSES.
ES8706964A1 (en) Method of affinity purification employing monoclonal antibodies.
DE68905934T2 (en) MATERIALS HEATABLE BY MICROWAVES.
DE68903576D1 (en) SIGNAL PEPTIDES EFFECTIVE IN YEAST AND THEIR USE FOR THE SECRETORIC EXPRESSION OF HETEROLOGICAL PROTEINS.
NZ220560A (en) Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen; apparatus therefor
AU525403B2 (en) Purified antigen
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
ATA116482A (en) PRE-FABRIC GROUND CARRIER FOR THE QUALITATIVE AND QUANTITATIVE DETERMINATION OF MICROORGANISMS
DE58904713D1 (en) USE OF ZINC OR IRON HYDROXIDE FOR ADJUVING ANTIQUE SOLUTIONS AND IN THIS WAY ADJUVED ANTIQUE SOLUTIONS.
GB2153364B (en) Lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
EP0131627A4 (en) Specific cea-family antigens, antibodies specific thereto and their methods of use.
SE8702463D0 (en) LIGANDS AND METHODS FOR AUGMENTING B-CELL PROLIFERATION
IT8619032A0 (en) IMPROVEMENTS MADE TO THE TREATMENT OF PARTICULATE MATERIALS.
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
GB2146351A (en) Monoclonal antibody
ATE40216T1 (en) MONOCLONAL ANTIBODY.
NO173831C (en) New monoclonal antibodies to IFN-omega, hybridomas for their preparation and use for purification, as well as the detection or quantitative determination of IFN-omega, and seen for use in the detection
DE68907377T2 (en) Agent and device for the determination of antigens or antibodies.
DE58905961D1 (en) Ultracentrifuge for the determination of particle size distributions.
DE3468324D1 (en) Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
ATE136469T1 (en) NEW USE OF A MONOCLONAL ANTIBODY
DE3367599D1 (en) Iodine-labelled radioactive estratriene derivatives, process and intermediates for their preparation, their use in radioimmuno assays and in the preparation of antigens, and antigens so obtained

Legal Events

Date Code Title Description
NUG Patent has lapsed